Effect of the combined treatment with Golgi disrupting agents and Actinomycin D or Vinblastine on the apoptosis of MDA-MB-231 cells.

<p>(A) Cells were left untreated, or transfected to transiently express the HA-epitope-tagged ARF1 constitutively-activated mutant (<i>ARF1</i>) for 16 h. Untransfected cells were left untreated for further 12 h (<i>Control</i>), or treated 12 h either with 10 ng/ml Actinomycin D (<i>ActD</i>) or 25 nM Vinblastine (<i>VLB</i>). Transfected cells were left untreated for further 12 h (<i>ARF1</i>), or treated 12 h either with 10 ng/ml Actinomycin D (<i>ARF1 + ActD</i>) or 25 nM Vinblastine (<i>ARF1 + VLB</i>). (B) Cells were left untreated for 12 h (<i>Control</i>), or treated 12 h either with 5 μg/ml Brefeldin A (<i>BFA</i>), 10 ng/ml Actinomycin D (<i>ActD</i>) or 25 nM Vinblastine (<i>VLB</i>), or with BFA in conjunction either with ActD (<i>BFA + ActD</i>) or VLB (<i>BFA + VLB</i>). (C) Cells were left untreated for 12 h (<i>Control</i>), or treated 12 h either with 10 μM Golgicide A (<i>GCA</i>), 10 ng/ml Actinomycin D (<i>ActD</i>) or 25 nM Vinblastine (<i>VLB</i>), or with GCA in conjunction either with ActD (<i>GCA + ActD</i>) or VLB (<i>GCA + VLB</i>). (A-C) Graphs depict the quantification of the number of cells decorated with Alexa-488-conjugated Annexin V. Bar represents the mean ± standard deviation (n = 3). * <i>P</i> < 0.05; ** <i>P</i> < 0.01; *** <i>P</i> < 0.001; ns, not statistically significant.